Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap Platform at Digestive Disease Week 2024
Four clinical device performance studies successfully demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions and eating schedulesSAN DIEG
Express News | HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target
Biora Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 2043.16% HC Wainwright & Co. → $15 Reiterates Buy → Buy 01/02/2024 7043.88% HC Wainwright & Co.
Biora Therapeutics: A Strong Buy on Robust Q1 Performance and Promising Drug Delivery Platforms
Biora Therapeutics | 10-Q: Quarterly report
Earnings Call Summary | Biora Therapeutics(BIOR.US) Q1 2024 Earnings Conference
The following is a summary of the Biora Therapeutics, Inc. (BIOR) Q1 2024 Earnings Call Transcript:Financial Performance:Biora Therapeutics reported operating expenses of $40.5 million, mainly due to
Express News | Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Express News | Biora Therapeutics Q1 Basic EPS USD -0.14
Express News | Biora Therapeutics Q1 Pretax Profit USD -4.141 Million
Express News | Biora Therapeutics Q1 Revenue USD 542 Thousand
Express News | Biora Therapeutics Q1 Net Income USD -4.189 Million
Notable Earnings After Wednesday's Close
Express News | Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap Oral Delivery Platform at Digestive Disease Week 2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data
Express News | Biora Therapeutics Inc - Final Results Are Expected to Be Available in Late Q2 2024
Express News | Biora Therapeutics Announces Completion of Multiple-Ascending Dose (Mad) Cohorts for Clinical Trial of Bt-600
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
Biora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery Innovations
Biora Therapeutics Files to Sell 10.7M Common Shares for Holders
Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company's BioJet platform for oral, sy